MedTrace Logo

Optical Genome Mapping in Characterization of Multiple Myeloma

NCT05786105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2024-03-13

No results posted yet for this study

Summary

The current cytogenetic characterization of Multiple Myeloma (including chromosome and gene abnormalities identification in abnormal plasma cells) encounters some limitations. Indeed current techniques only enable to analyze a limited numbers of predefined abnormalities. New tools that will allow for characterization of abnormalities involved in multiple myeloma development are thus required. The interest of Optical Genome Mapping has already been demonstrated in other hematological diseases. The present study aims at validating Optical Genome Mapping in genetic abnormalities identification for patients with Multiple Myeloma (MM).

Conditions

Interventions

OTHER

Bone Marrow samples collection

Bone Marrow samples collection - one ethylenediaminetetraacetic acid (EDTA) tube - for Optical Genome Mapping

Sponsors & Collaborators

  • GENTYANE (GEnoTYpage and sequencing in AuvergNE)

    collaborator UNKNOWN

  • Hôpitaux Universitaires de Strasbourg

    collaborator UNKNOWN

  • Institut de cancérologie Strasbourg Europe

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-21
Primary Completion
2023-11-21
Completion
2023-11-21

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05786105 on ClinicalTrials.gov